TMTaraneh Moini-Zanjani

Taraneh Moini-Zanjani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taraneh Moini-Zanjani has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Masoumeh Sabetkasaei

    Department of Pharmacology & Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    4 shared publications
  • Elham Saghaei

    Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

    2 shared publications
  • Kobra Naseri

    Medical toxicology and Drug Abuse Research Center, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

    2 shared publications
  • Malek Zarei

    Department of Pharmacology & Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Yalda Khazaei-Poul

    Department of Pharmacology & Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Ahad Khalilnezhad

    Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

    1 shared publication

Latest Publications

  • Carbamazepine effects on pain management and serum IL-6, IL-10 evaluation in addicted patients undergoing surgery

    by Alireza Salimi, Masoumeh Sabetkasaei, Hanna Raisi, Farzaneh Labibi, Haleh Ameli, Yalda Khazaei-Poul, Malek Zarei, Kamran Mottaghi, Farhad Safari, Ali Nazem-Bokaei, et al.


  • Open Access

    Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line

    by Faezeh Khodaie, Yalda Khazaei-Poul, Taraneh Moini-Zanjani

    Background: Skin cancer is one of the most common types of cancer worldwide and non-steroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of cancers. Objectives: In this study we aimed to evaluate the cytotoxic effects of piroxicam (a non-selective cyclooxygenase (COX) inhibitor) and nimesulide (a highly selective COX-2 inhibitor) on A431 human squamous carcinoma cell line. Methods: Squamous carcinoma cell line (A431) was cultured in RPMI medium containing 10% FBS and penicillin-streptomycin at 37°C and 5% CO2. Cells were treated with different concentrations of piroxicam and nimesulide (100 - 1000 µmol/L) for 24, 48 and 72 hours (h). Anti-proliferative effects were determined using MTT colorimetric assay. Results: Piroxicam and nimesulide reduced cell viability in a time and concentration dependent manner. The most cytotoxic effect was produced in 72 hours incubation time. The IC50 value of nimesulide was significantly lower than piroxicam in 24 and 72 hours, but not in 48 hours treatment duration. Conclusions: This study demonstrates that the administration of a highly selective COX-2 inhibitor could probably be more effective than a non-selective NSAID in reducing cancer cells proliferation and that COX-2 can possibly play an important role in skin cancer development. Keywords: Piroxicam; Nimesulide; Squamous Cell Carcinoma


  • Open Access

    Paradoxical effect of minocycline on established neuropathic pain in rat

    by Malek Zarei, Masoumeh Sabetkasaei, Taraneh Moini-Zanjani

    Neuropathic pain occurs after peripheral nerve damage, inflammation or infection. In this situation, microglial cells become activated and play a key role in producing pain. Minocycline (microglia inhibitor), was reported to reduce pain when used preventively. However, it seems that, when used after nerve injury, results in its pain reducing effects are different. In this regard, to assess the pain reducing differences of minocycline, neuropathic pain was induced by the ligation of the sciatic nerve in the rat which is recognized as chronic constriction injury (CCI) and minocycline was administered before and after sciatic nerve injury. Wistar male rats (200-250 g, n=6) were used in these experiments. Rats were distributed in various groups: vehicle-treated CCI (control), sham-operated and minocycline-treated CCI groups. In the first part of the experiment (pre-injury study), minocycline (10, 20, 30 and 40 mg/kg,) was injected one hour before surgery and then daily for two weeks. In the second part (post injury study), minocycline was administered: 1: at day one after nerve damage once a day to day 14, 2: at day seven after surgery and continued daily until day 14. Analgesimeter for thermal hyperalgesia and von Frey hairs for mechanical allodynia were used to evaluate pain behavior. Thermal hyperalgesia and mechanical allodynia were attenuated significantly, when minocycline used before surgery, while it was not able to reduce pain behavior administered after surgery. It seems that, in spite of what some previous studies have reported, here, minocycline is not able to attenuate established neuropathic pain.


  • Open Access

    The Effect of Rapamycin on Oxidative Stress in MCF-7 and MDA MB-231 Human Breast Cancer Cell Lines

    by Hadi Kalantar, Masoumeh Sabetkasaei, Ali Shahriari, Mostafa Haj Molla Hoseini, Siavash Mansouri, Mojtaba Kalantar, Azin Kalantari, Yalda Khazaei Poul, Farazaneh Labibi, Taraneh Moini-Zanjani

    Background: Mammalian target of rapamycin (mTOR) is a kinase pathway that regulates the cell cycle progression and growth. Rapamycin inhibits this pathway. The useful effects of rapamycin on cell growth have been widely shown in animal studies. However, its beneficial effects are associated with some success in benign and malignant cancers, which have produced its moderate outcomes in the clinic. Objectives: The aim of this study was to investigate whether rapamycin can induce oxidative stress in MCF-7 and MDA MB-231 human breast cancer cell lines. Methods: The MCF-7 and MDA MB-231 cell lines were cultivated and treated with rapamycin for 72 hours. The viability of the cells was determined using the colorimetric MTT assay. Lipid peroxidation (TBARS), protein oxidation (carbonyl groups), total antioxidant capacity assay, and glutathione (GSH) levels were measured in the MCF-7 and MDA MB-231 cells both with and without rapamycin treatment. Results: The IC50 concentration of rapamycin was 100 nM in MCF-7 cells, whereas the MDA-MB-231 cells were highly resistant to rapamycin. Our data indicated an increase in oxidative status by increasing lipid peroxidation and protein oxidation, GSH, and total antioxidant capacity levels in the MCF-7 and MDA-MB-231 cell lines exposed to rapamycin in comparison with control cells. Conclusions: These outcomes support our theory that rapamycin increases oxidative stress in MCF-7 and MDA MB-231 cells but also shows high levels of antioxidant effects, which probably limit the effects of the rapamycin on the same issue in the clinic. Keywords: Rapamycin; MCF-7 Cells; MDA-MB231 Cells; Breast Cancer; Oxidative Stress; Antioxidants


  • Open Access

    Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells

    by Mohsen Rashidi, Seyed Ali Ziai, Taraneh Moini Zanjani, Ahad Khalilnezhad, Hamidreza Jamshidi, Davar Amani

    Background: Resistance to chemotherapy is a growing concern, thus natural anticancer agents are drawing the attention of many scientists and clinicians. One natural anticancer agent, umbelliprenin, is a coumarin produced by many species of Ferula. Objectives: We aimed to examine the inhibitory effect of umbelliprenin on human and mouse bone marrow-derived stem cells (BMDSCs), peripheral blood mononuclear cells (PBMCs), and different cancer cell lines. Materials and Methods: In this in vitro experimental study, the HT29, CT26, MCF-7, 4T1, A172, and GL26 cancer cells and human and mouse BMDSCs and PBMCs were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), incubated at 37°C for 24 hours in a 5% CO2 atmosphere, and then were treated with different concentrations of umbelliprenin dissolved in dimethyl sulfoxide (DMSO) (3, 6, 12, 25, 50, 100, and 200 µg/mL) for 24, 48, and 72 hours at 37°C. Each experiment was performed in triplicate. Finally, the cell survival rate was assessed by MTT assay. The IC50 values were calculated based on the log values using GraphPad Prism version 5 software for windows (La Jolla CA, USA) and were expressed as mean ± SEM. Results: Umbelliprenin inhibited the cancer cells in a concentration-dependent (P < 0.05) but not time-dependent manner (P > 0.05). The most sensitive and resistant cell lines at the 24-hour incubation time were 4T1 (IC50, 30.9 ± 3.1 µg/mL) and A172 (IC50, 51.9 ± 6.7 µg/mL); at the 48-hour incubation time: 4T1 (IC50, 30.6 ± 2.6 µg/mL) and CT26 (IC50, 53.2 ± 3.6 µg/mL); and at the 72-hour incubation time: HT29 (IC50, 37.1 ± 1.4 µg/mL) and 4T1 (IC50, 62.2 ± 4.8 µg/mL). Both human and mouse BMDSCs showed the highest resistance at the 24-hour incubation time (IC50s, 254.7 ± 21 and 204.4 ± 4.5 µg/mL, respectively) and the highest sensitivity at the 72-hour incubation time (IC50s, 120.4 ± 5 and 159.0 ± 7.3 µg/mL, respectively). The PBMCs of both human and mouse origin revealed very strong resistance to the studied concentrations of umbelliprenin (IC50s ranging from 713.5 ± 499.1 to 6651 ± 3670.7 µg/mL). Conclusions: Our findings indicate that umbelliprenin exhibits concentration-dependent inhibitory effects on various cell types; it is potentially toxic against the HT29, CT26, MCF-7, 4T1, A172, and GL26 cell lines, potentially harmful against BMDSCs, and non-toxic against PBMCs. Therefore, if our results are approved in the future, umbelliprenin can be an appropriate candidate for developing treatments against different cancers. Keywords: Inhibition; Neoplastic Cell; Natural Product; Umbelliprenin


  • Open Access

    Enhancement of Antinociception by Co-administrations of Nefopam, Morphine, and Nimesulide in a Rat Model of Neuropathic Pain

    by Elham Saghaei, Taraneh Moini Zanjani, Masoumeh Sabetkasaei, Kobra Naseri

    Saghaei E, et al. Korean J Pain. 2012 Jan;25(1):7-15. https://doi.org/10.3344/kjp.2012.25.1.7


  • Carbamazepine potentiates morphine analgesia on postoperative pain in morphine-dependent rats

    by Kobra Naseri, Masoumeh Sabetkasaei, Taraneh Moini Zanjani, Elham Saghaei